Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  American Society of Nephrology. Clinical Journal

• Publication date

  2014-05-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.2215/CJN.02650313PMID 24721888PMCID PMC4011437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications.

  2012cited by this paper
• Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease.

  2012cited by this paper
• Detected renal cysts are tips of the iceberg in adults with ADPKD.

  2012cited by this paper
• Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

  2012cited by this paper
• Mammalian target of rapamycin and the kidney. I. The signaling pathway.

  2012cited by this paper
• Macrophages promote cyst growth in polycystic kidney disease.

  2011cited by this paper
• Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients.

  2011cited by this paper
• mTOR inhibitors and autosomal dominant polycystic kidney disease.

  2011cited by this paper
• Cystogenic potential of CD133+ progenitor cells of human polycystic kidneys

  2011cited by this paper
• mTOR inhibitors and autosomal dominant polycystic kidney disease.

  2011cited by this paper
• Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

  2010cited by this paper
• Sirolimus therapy to halt the progression of ADPKD.

  2010cited by this paper
• mTOR inhibitors in polycystic kidney disease.

  2010cited by this paper
• Novel targets for the treatment of autosomal dominant polycystic kidney disease

  2010cited by this paper
• Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level?

  2010cited by this paper
• The HALT polycystic kidney disease trials: design and implementation.

  2010cited by this paper
• Imaging for the prognosis of autosomal dominant polycystic kidney disease

  2010cited by this paper
• Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

  2010cited by this paper
• Everolimus in patients with autosomal dominant polycystic kidney disease.

  2010cited by this paper
• Autosomal dominant polycystic kidney disease: the last 3 years.

  2009cited by this paper
• A new equation to estimate glomerular filtration rate.

  2009cited by this paper
• Renal injury is a third hit promoting rapid development of adult polycystic kidney disease.

  2009cited by this paper
• Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).

  2009cited by this paper
• Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease.

  2009cited by this paper
• Family history of renal disease severity predicts the mutated gene in ADPKD.

  2009cited by this paper
• A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction

  2008cited by this paper
• The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway

  2008cited by this paper
• High sirolimus levels may induce focal segmental glomerulosclerosis de novo.

  2007cited by this paper
• PSGL‐1 and mTOR regulate translation of ROCK‐1 and physiological functions of macrophages

  2007cited by this paper
• Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

  2006cited by this paper
• Volume progression in polycystic kidney disease.

  2006cited by this paper
• Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.

  2006cited by this paper
• Nephrotic syndrome and IgA nephropathy in polycystic kidney disease

  2006cited by this paper
• Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.

  2006cited by this paper
• The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.

  2006cited by this paper
• Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

  2006cited by this paper
• A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis.

  2005cited by this paper
• Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.

  2004cited by this paper
• Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients1

  2003cited by this paper
• Macrophage colony‐stimulating factor‐dependent macrophage proliferation is mediated through a calcineurin‐independent but immunophilin‐dependent mechanism that mediates the activation of external regulated kinases

  2003cited by this paper
• Autosomal dominant polycystic kidney disease.

  2003cited by this paper
• Risk factors for hospitalizations resulting from pulmonary embolism after renal transplantation in the United States.

  2001cited by this paper
• Accuracy of volumetric measurements after virtual right hepatectomy in potential donors undergoing living adult liver transplantation.

  2001cited by this paper
• Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease.

  2000cited by this paper
• Compression of the inferior vena cava by right renal cysts: an unusual cause of IVC and/or iliofemoral thrombosis with pulmonary embolism in autosomal dominant polycystic kidney disease.

  1998cited by this paper
• Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease.

  1997cited by this paper
• The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I.

  1996cited by this paper
• Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group.

  1995cited by this paper
• Autosomal dominant polycystic kidney disease

  1992cited by this paper

• Pathogenic Pathways and Therapeutic Strategies in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  2025cites this paper
• Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity.

  2024cites this paper
• Rapamycin-associated nephropathy; a short look at the new findings

  2024cites this paper
• Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

  2024cites this paper
• Inflammation Is More Sensitive than Cell Proliferation in Response to Rapamycin Treatment in Polycystic Kidney Disease

  2024cites this paper
• Novel Potential Therapeutic Targets in Autosomal Dominant Polycystic Kidney Disease from the Perspective of Cell Polarity and Fibrosis

  2024cites this paper
• Inhibition of the Mechanistic Targets of Rapamycin Beyond Transplant Immunosuppression: A Mini-Review

  2023cites this paper
• Folate conjugated nanomedicines for selective inhibition of mTOR signaling in polycystic kidneys at clinically relevant doses.

  2023cites this paper
• Cystic Kidney Diseases in Children and Adults: Differences and Gaps in Clinical Management.

  2023cites this paper
• Crosstalk between the mTOR pathway and primary cilia in human diseases.

  2023cites this paper
• Clinical Quality Control of MRI Total Kidney Volume Measurements in Autosomal Dominant Polycystic Kidney Disease

  2023cites this paper
• Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans.

  2022cites this paper
• Molecular Mechanisms of Epigenetic Regulation, Inflammation, and Cell Death in ADPKD

  2022cites this paper
• Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease

  2022cites this paper
• A Systematic Review of Reported Outcomes in ADPKD Studies

  2022cites this paper
• Indoxyl Sulfate Contributes to mTORC1-Induced Renal Fibrosis via The OAT/NADPH Oxidase/ROS Pathway

  2021cites this paper
• Heterogeneity of cell composition and origin identified by single-cell transcriptomics in renal cysts of patients with autosomal dominant polycystic kidney disease

  2021cites this paper
• mTOR Signaling in Kidney Diseases.

  2020cites this paper
• Autophagy in kidney disease: Advances and therapeutic potential.

  2020cites this paper
• Lowe syndrome patient cells display mTOR- and RhoGTPase-dependent phenotypes alleviated by rapamycin and statins.

  2020cites this paper
• Autosomal dominant polycystic kidney disease

  2019cites this paper
• A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease

  2019cites this paper
• Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis

  2019cites this paper
• AKT signaling promotes DNA damage accumulation and proliferation in polycystic kidney disease.

  2019cites this paper
• The PI3K/Akt/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium.

  2019cites this paper
• Renal disease in tuberous sclerosis complex: pathogenesis and therapy

  2018cites this paper
• Long noncoding RNA Hoxb3os is dysregulated in autosomal dominant polycystic kidney disease and regulates mTOR signaling

  2018cites this paper
• Recent advances of mTOR inhibitors use in autosomal dominant polycystic kidney disease: is the road still open?

  2018cites this paper
• Renal injury progression in autosomal dominant polycystic kidney disease: a look beyond the cysts.

  2018cites this paper
• Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.

  2018cites this paper
• New Therapies Targeting Cystogenesis in Autosomal Polycystic Kidney Disease

  2017cites this paper
• Novel Therapeutic Strategies Targeting Molecular Pathways of Cystogenesis in Autosomal Polycystic Kidney Disease

  2017cites this paper
• Rapamycin treatment dose‐dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell‐cycle‐associated CDK1/cyclin axis

  2017cites this paper
• New treatment paradigms for ADPKD: moving towards precision medicine

  2017cites this paper
• m-TOR Inhibitors in the Current Practice

  2017influential citation
• Machine Learning Methods for Segmentation in Autosomal Dominant Polycystic Kidney Disease

  2017cites this paper
• Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease

  2017cites this paper
• Recent advances in management of autosomal‐dominant polycystic kidney disease

  2017cites this paper
• Diagnosis and Treatment Status and Progress of Autosomal Dominant Polycystic Kidney Disease

  2017cites this paper
• Diagnosis and Treatment Status and Progress of Autosomal Dominant Polycystic Kidney Disease

  2017cites this paper
• Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor.

  2017cites this paper
• New options for the management of polycystic kidney disease

  2016cites this paper
• Polycystic Kidney Disease , Autosomal Dominant Synonym : ADPKD

  2016cites this paper
• Roles of mTOR complexes in the kidney: implications for renal disease and transplantation

  2016cites this paper
• Nephronophthisis: should we target cysts or fibrosis?

  2016cites this paper
• Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.

  2016cites this paper
• The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees.

  2015cites this paper
• Lipopolysaccharide Induces Chronic Kidney Injury and Fibrosis through Activation of mTOR Signaling in Macrophages

  2015cites this paper
• Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial

  2015cites this paper
• Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease

  2015cites this paper
• Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy.

  2015cites this paper
• Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease.

  2015cites this paper
• Current management of autosomal dominant polycystic kidney disease.

  2015cites this paper
• Novel therapeutic approaches to autosomal dominant polycystic kidney disease.

  2015cites this paper
• Autosomal dominant polycystic kidney disease: the changing face of clinical management

  2015cites this paper
• An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease

  2015cites this paper
• The Treatment of Autosomal Dominant Polycystic Kidney Disease.

  2015cites this paper
• AVANÇOS NO TRATAMENTO DA DOENÇA RENAL POLIQUÍSTICA AUTOSSÓMICA DOMINANTE

  2015cites this paper
• Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trials: A Critical Appraisal

  2015cites this paper
• Implications of Dysfunction of Mechanosensory Cilia in Polycystic Kidney Disease

  2015cites this paper
• Pathophysiologie, épidémiologie, présentation clinique, diagnostic et options thérapeutiques dans la polykystose rénale autosomique dominante

  2015cites this paper
• Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

  2015cites this paper
• [Pathophysiology, epidemiology, clinical presentation, diagnosis and treatment options for autosomal dominant polycystic kidney disease].

  2015cites this paper
• Cystic and noncystic complications of ADPKD CYSTIC COMPLICATIONS Renal cysts Hypertension Pain Bleeding Urinary tract infection Infected cyst Renal stones Urinary tract obstruction Progressive enlargement

  2014cites this paper
• Advances in autosomal dominant polycystic kidney disease—2014 and beyond

  2014cites this paper
• Autosomal dominant polycystic kidney disease: genetics, epidemiology, and treatment

  2014cites this paper
• Novel treatments of autosomal dominant polycystic kidney disease.

  2014cites this paper